(Q45913193)

English

Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

scientific article published on 3 November 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

Health utilities in relation to treatment response and adverse events in relapsed/refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

author name string

Paul Swinburn

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

Sarah Shingler

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

Sarah Acaster

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

Andrew Lloyd

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

Vijayveer Bonthapally

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

publication date

3 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

56

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

1839-1845

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Hodgkin's lymphoma in adults

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Fatigue in long-term Hodgkin's Disease survivors: a follow-up study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Fatigue in long-term survivors of Hodgkin‘s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG)

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Measurement of health state utilities for economic appraisal

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Health state utilities for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Health state utilities for non small cell lung cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

The time trade-off method: results from a general population study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Utility values among glaucoma patients: an impact on the quality of life

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

EQ-5D™-derived utility values for different levels of migraine severity from a UK sample of migraineurs

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2014.970542

21 January 2018

Identifiers

10.3109/10428194.2014.970542

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/25284490

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45913193&oldid=1521016930"